CytomX Therapeutics Appoints Dr. Charles Fuchs to Board

What Happened CytomX Therapeutics, Inc. announced in an 8-K that on July 24, 2026 it appointed Charles Fuchs, M.D., M.P.H., to its Board of Directors as a Class II director, effective immediately. Dr. Fuchs’s initial term runs until the Company’s 2029 annual meeting of stockholders.

Key Details

• Equity grant: Dr. Fuchs received an option to purchase 118,000 shares under the Company’s 2015 Equity Incentive Plan.
• Exercise price & vesting: Exercise price equals the closing price of CytomX common stock on July 24, 2026; the option vests 1/36th monthly, subject to continued service.
• Compensation & indemnity: He will receive the Company’s standard non-employee director compensation and will enter into the Company’s standard indemnification agreement (form previously filed as Exhibit 10.16 to the S-1).
• Related-party disclosure: No transactions since the start of the Company’s last fiscal year (nor proposed transactions) involving amounts > $120,000 in which Dr. Fuchs had a material interest; no special arrangements or understandings led to his appointment.

Why It Matters A new director changes the Board makeup and may influence corporate governance and oversight. For investors, the grant and vesting schedule show the company’s standard approach to compensating non-employee directors with equity incentives, which can align director interests with shareholders. The filing contains no other material financial results or departures.